PaccMann^RL on SARS-CoV-2: Designing antiviral candidates with conditional generative models

by   Jannis Born, et al.

With the fast development of COVID-19 into a global pandemic, scientists around the globe are desperately searching for effective antiviral therapeutic agents. Bridging systems biology and drug discovery, we propose a deep learning framework for conditional de novo design of antiviral candidate drugs tailored against given protein targets. First, we train a multimodal ligand–protein binding affinity model on predicting affinities of antiviral compounds to target proteins and couple this model with pharmacological toxicity predictors. Exploiting this multi-objective as a reward function of a conditional molecular generator (consisting of two VAEs), we showcase a framework that navigates the chemical space toward regions with more antiviral molecules. Specifically, we explore a challenging setting of generating ligands against unseen protein targets by performing a leave-one-out-cross-validation on 41 SARS-CoV-2-related target proteins. Using deep RL, it is demonstrated that in 35 out of 41 cases, the generation is biased towards sampling more binding ligands, with an average increase of 83 potential Envelope-protein inhibitor and perform a synthetic accessibility assessment of the best generated molecules is performed that resembles a viable roadmap towards a rapid in-vitro evaluation of potential SARS-CoV-2 inhibitors.


page 1

page 2

page 3

page 4

page 5

page 6


Targeted design of antiviral compounds against SARS-CoV-2 with conditional generative models

With the fast development of COVID-19 into a global pandemic, scientists...

De novo design of protein target specific scaffold-based Inhibitors via Reinforcement Learning

Efficient design and discovery of target-driven molecules is a critical ...

Designing a Prospective COVID-19 Therapeutic with Reinforcement Learning

The SARS-CoV-2 pandemic has created a global race for a cure. One approa...

DiffDTM: A conditional structure-free framework for bioactive molecules generation targeted for dual proteins

Advances in deep generative models shed light on de novo molecule genera...

Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework

The COVID-19 pandemic has highlighted the urgency for developing more ef...

Quantum Generative Models for Small Molecule Drug Discovery

Existing drug discovery pipelines take 5-10 years and cost billions of d...

SILVR: Guided Diffusion for Molecule Generation

Computationally generating novel synthetically accessible compounds with...

Please sign up or login with your details

Forgot password? Click here to reset